Cathal Friel of Open Orphan, Andy Hollingworth from Toople, Gil Holzman at Eco Atlantic & Vadim Alexandre on an IPO
If you find this podcast useful please give it a rating and review on iTunes by clicking here
On today's Vox Markets Podcast: Cathal Friel of Open Orphan, Andy Hollingworth from Toople, Gil Holzman at Eco Atlantic & Vadim Alexandre on an IPO
Cathal Friel, Executive Chairman of Open Orphan #ORPH discusses their final results and demerger of Poolbeg Pharma.
Open Orphan plc (London and Euronext: ORPH) is a rapidly growing pharmaceutical service/contract research company that is a world leader in testing vaccines and antivirals using human challenge clinical trials. The company provides services to Big Pharma, biotech and government/public health organisations.
Andy Hollingworth, CEO at Toople #TOOP talks about their interim results which saw an increase in both gross profit and gross margin.
Toople.com provides bespoke telecoms services for its fast growing target market of UK SMEs with between one and 500 employees. Services offered by the Group include business broadband, fibre, EFM and Ethernet data services, business mobile phones, cloud PBX and SIP Trunking and Traditional Services (calls and lines) all of which are delivered and managed via the Group's proprietary software platform.
(Interview starts at 8 minutes 36 seconds)
Gil Holzman President & Chief Executive Officer Eco Atlantic Oil & Gas #ECO discusses their projects and upcoming milestones.
Eco Atlantic is a TSX-V and AIM quoted Oil & Gas exploration and production Company with interests in Guyana and Namibia, where significant oil discoveries have been made. (Interview starts at 20 minutes 50 seconds)
Vadim Alexandre, Head of Healthcare at SP Angel discusses Spectral MD a company IPO'ing soon, which develops technology using predictive analytics and AI algorithms to help clinicians make more accurate and faster treatment decisions.
(Interview starts at 30 minutes 50 seconds)
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.